Claims for Patent: 8,062,643

Summary for Patent: 8,062,643

Title:	Use of neurotoxin therapy for treatment of urologic and related disorders
Abstract:	The present invention related to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.
Inventor(s):	Schmidt; Richard A (Arvada, CO)
Assignee:	The Regents of the University of Colorado (Boulder, CO)
Application Number:	11/925,938
Patent Claims:	1. A method for treating an urge type dysfunction in a patient, comprising administering a therapeutically effective amount of between 1.4 IU/kg to 17.1 IU/kg of botulinum toxin to a lateral bladder wall of the bladder of the patient, whereby the urge type dysfunction is treated. 2. The method of claim 1, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G. 3. The method of claim 2, wherein the botulinum toxin is botulinum toxin type A. 4. The method of claim 3, wherein administration is to a bladder wall and administration is by single or serial injection. 5. The method of claim 3, wherein the therapeutically effective amount of botulinum toxin type A is 200 IU of botulinum toxin type A. 6. The method of claim 3, wherein the therapeutically effective amount of botulinum toxin type A is 400 IU of botulinum toxin type A. 7. The method of claim 3, wherein the therapeutically effective amount of botulinum toxin type A is 400 IU of botulinum toxin type A administered serially. 8. The method of claim 1, wherein administration is by injection. 9. The method of claim 8, wherein injection comprises a single injection. 10. The method of claim 8, wherein injection comprises serial injection. 11. The method of claim 1, wherein treating the urge type dysfunction provides the patient with sleep through the night that is uninterrupted by an urge to urinate. 12. The method of claim 1, wherein the botulinum toxin is administered in a pharmaceutically acceptable formulation. 13. A method for treating an urge type dysfunction in a patient, the method comprising administering, via injection, a therapeutically effective amount of between about 1.4 IU/kg and about 17.1 IU/kg of a botulinum toxin type A to a bladder of the patient, whereby the urge type dysfunction is treated. 14. The method of claim 13, wherein the therapeutically effective amount of botulinum toxin type A is 200 IU of botulinum toxin type A. 15. The method of claim 13, wherein the therapeutically effective amount of botulinum toxin type A is 400 IU of botulinum toxin type A. 16. The method of claim 13, wherein the therapeutically effective amount of botulinum toxin type A is 400 IU of botulinum toxin type A administered serially. 17. The method of claim 13, wherein the therapeutically effective amount is provided as a single dose. 18. The method of claim 13, wherein the therapeutically effective amount is provided as a divided dose. 19. The method of claim 13, wherein frequency of urination during sleep is reduced. 20. The method of claim 13, wherein the therapeutically effective amount is administered to a lateral wall of the bladder. 21. The method of claim 13, wherein the botulinum toxin is administered in a pharmaceutically acceptable formulation.

Details for Patent 8,062,643

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	BOTOX COSMETIC	onabotulinumtoxina	For Injection	103000	December 09, 1991		2017-07-15
Abbvie Inc.	BOTOX	onabotulinumtoxina	For Injection	103000	December 09, 1991		2017-07-15

International Patent Family for US Patent 8,062,643

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	9903483
United States of America	9066943
United States of America	8840905